Immunome Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | — | — |
| Operating income | -$224.1M | -$305.8M | -$109.5M | -$36.9M | -$25.2M |
| Operating expenses | $231.1M | $314.8M | $123.5M | $36.9M | $25.2M |
| Cash from operations | -$190.9M | -$110.8M | -$7.6M | -$28.7M | -$18.2M |
| Capital expenditure | $9.7M | $7.2M | $831,000 | $248,000 | $79,000 |
| Free cash flow | -$200.6M | -$118.0M | -$8.4M | -$28.9M | -$18.3M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $683.2M | $240.2M | $148.5M | $24.0M | $57.9M |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.4M | $9.7M |
Shares outstanding 113.3M · Free float 83.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.